Degron Therapeutics vs Ray Therapeutics
Degron Therapeutics vs Ray Therapeutics, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Degron Therapeutics is on 62/100 and Ray Therapeutics on 53/100.
Where each one leads
Degron Therapeutics
- our overall score: 62/100 against 53/100
- agent readiness: 27/100 against 21/100
Ray Therapeutics
- domain rating: 29/100 against 24/100
- funding raised: $243M against $40.0M
At a glance
| Measure | Degron Therapeutics | Ray Therapeutics |
|---|---|---|
| What it is | Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines. | Pioneering vision restoration therapies for severe retinal degenerations. |
| Category | Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare | Biotechnology, Pharmaceuticals, Healthcare, Medical Devices |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Services |
| Founded | 2020 | 2021 |
| Headquarters | San Diego, USA | Berkeley, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | Degron Therapeutics | Ray Therapeutics |
|---|---|---|
| Employees | 24 | Not published |
| Total funding | $40.0M | $243M |
| Latest round | Series A Extension | Series B |
| Valuation | $1.1B | Not published |
| LinkedIn followers | 1,380 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Degron Therapeutics | Ray Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 62/100 | 53/100 |
| Traction | Not published | 40/100 |
| Team | 24/100 | 50/100 |
| Search visibility | 57/100 | 14/100 |
| Quality | Not published | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (27/100) | F (21/100) |
| Domain ratingLink authority, 0-100 | 24/100 | 29/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Degron Therapeutics | Ray Therapeutics |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Analytics 4 |
Degron Therapeutics vs Ray Therapeutics: common questions
Which is better, Degron Therapeutics or Ray Therapeutics?
On our 0-100 score Degron Therapeutics rates higher (62/100 against 53/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Degron Therapeutics and Ray Therapeutics compare on the numbers?
Degron Therapeutics leads on our overall score (62/100 against 53/100), agent readiness (27/100 against 21/100). Ray Therapeutics leads on domain rating (29/100 against 24/100), funding raised ($243M against $40.0M).
Read the full Degron Therapeutics review and pricing or the Ray Therapeutics review and pricing. You can also browse other Degron Therapeutics alternatives we track.